A PHASE-II TRIAL OF 5-FLUOROURACIL, FOLINIC ACID, VINORELBINE IN PRETREATED PATIENTS WITH METASTIC COLORECTAL-CANCER

IAFFAIOLI,RV; FACCHINI,G; TORTORIELLO,A; CAPONIGRO,F; GESUE,G; FINIZIO,A; DIMARTINO,N; DESENA,G; ANTONELLI,B; SCARAMELLINO,G; FEI,L; SANTANGELO,M; BUCCI,L

doi:10.3892/or.2.4.513

A PHASE-II TRIAL OF 5-FLUOROURACIL, FOLINIC ACID, VINORELBINE IN PRETREATED PATIENTS WITH METASTIC COLORECTAL-CANCER

Authors:
- RV IAFFAIOLI
- G FACCHINI
- A TORTORIELLO
- F CAPONIGRO
- G GESUE
- A FINIZIO
- N DIMARTINO
- G DESENA
- B ANTONELLI
- G SCARAMELLINO
- L FEI
- M SANTANGELO
- L BUCCI
View Affiliations

Affiliations: UNIV CAGLIARI,IST MED INTERNA,I-09124 CAGLIARI,ITALY. IST MED LEGALE AM,MILAN,ITALY. UNIV NAPLES 2,NAPLES,ITALY. OSPED AVELLINO,DIV CHIRURG,AVELLINO,ITALY.
Published online on: July 1, 1995 https://doi.org/10.3892/or.2.4.513
Pages: 513-516

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

43 patients with metastatic colorectal Cancer pretreated with 5-fluorouracil-based chemotherapy received vinorelbine plus 5-fluorouracil plus folinic acid with the aim of evaluating vinorelbine activity in advanced colorectal cancer and its potential synergism with commonly used drugs. 9 partial responses were observed, for an;overall objective response rate of 20.9%. 20 additional patients had stable disease (46.5%). Median duration of response was 7 months. Median survival from the start of treatment was 6 months. The main toxic effect was myelosuppression. We conclude that our regimen is active enough to warrant further evaluation in advanced colorectal cancer.